[Catecholamine metabolism in different forms of Parkinson's disease]

Area of Science:

• Neuroscience
• Biochemistry
• Metabolomics

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder affecting dopamine-producing neurons.
• Understanding catecholamine metabolism is crucial for diagnosing and managing PD.
• Peripheral markers of dopamine metabolism require further investigation for clinical utility.

Purpose of the Study:

• To evaluate catecholamine metabolism via daily urine excretion in Parkinson's disease patients.
• To identify informative peripheral markers for dopamine metabolism in PD.
• To correlate metabolic markers with clinical subtypes and symptom severity.

Main Methods:

• Daily urine samples were collected from patients with tremor-dominant and rigid/akinetic PD.
• Analysis of urinary excretion of DOPA (3,4-dihydroxyphenylalanine) and DOPAA (3,4-dioxyphenylacetic acid).
• Assessment of the DOPA/DOPAA ratio as a marker of dopamine metabolism.

Main Results:

• DOPA excretion and the DOPA/DOPAA ratio were identified as key peripheral markers.
• Early-stage PD showed decreased free dopamine and noradrenaline, with intensified dopamine metabolism (lower DOPA/DOPAA ratio).
• Rigid/akinetic PD patients exhibited lower DOPAA and DOPA excretion compared to tremor-dominant patients.
• Treated patients demonstrated correlations between urinary DOPA, DOPA/DOPAA ratio, and neurological symptom severity.

Conclusions:

• Urinary DOPA and DOPAA levels, along with the DOPA/DOPA/DOPAA ratio, are valuable peripheral markers for assessing dopamine metabolism in Parkinson's disease.
• These markers can help differentiate PD subtypes and reflect disease severity, particularly in treated individuals.
• Further research into these metabolic profiles may aid in PD diagnosis and treatment monitoring.